More common than we thought: Hypermobile Ehlers-Danlos Syndrome, comorbidity burden, and long COVID risk in a national cohort
PLOS Digital Health · 05.11.2026 · 5 (11) · e0001707
DOI: 10.1371/journal.pdig.0001707 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Digital Health, online erschienen am 05.11.2026. Verfasst von Megan L Pearson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Gates Institute, University of Colorado Anschutz, Aurora, Colorado, United States of America. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIGMS NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
Hypermobile Ehlers-Danlos Syndrome (hEDS) is a complex, underdiagnosed connective tissue disorder characterized by widespread symptoms affecting multiple organ systems. Recent clinical observations suggest that individuals with hEDS may be at increased risk for persistent symptoms following COVID-19, commonly referred to as Long COVID. Using data from over 19 million patients across the United States, we examined associations between hEDS, COVID-19 infection, Long COVID, and related chronic conditions. We identified just over 25,000 individuals with hEDS and estimated a prevalence of approximately 1 in 800, which is higher than previously recognized. Despite similar rates of COVID-19 infection between patients with hEDS and matched controls, patients with hEDS were nearly three times more likely to develop Long COVID. This risk was concentrated among patients with hEDS who also had overlapping conditions commonly seen in post-viral syndromes, including autonomic dysfunction (POTS), immune dysregulation (MCAS), and chronic fatigue (ME/CFS). Patients with hEDS also exhibited higher odds of having additional risk factors for severe or prolonged illness, including chronic lung and autoimmune conditions, depression, and cerebrovascular disease. A subgroup of patients received their hEDS diagnosis only after a COVID-19 or Long COVID diagnosis, and this subgroup was highly enriched for multimorbidity, particularly POTS and MCAS. These findings establish hEDS as more prevalent than previously recognized and identify a substantially elevated, comorbidity-driven risk of Long COVID in this population. Improved screening, earlier diagnosis, and integrated care pathways are urgently needed to support this complex and underserved patient group.
Autor:innen und Institutionen
- Department of Dermatology, Gates Institute, University of Colorado Anschutz, Aurora, Colorado, United States of America.
- Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
- Department of Pediatrics and Genetics, Children's Hospital Colorado, Aurora, Colorado, United States of America.
ORCID-Profile: Megan L Pearson, Bryan J Laraway
Förderung
- NCATS NIH HHS
- NIGMS NIH HHS
- NIAMS NIH HHS
- National Center for Advancing Translational Sciences
- National Institutes of Health
Zitieren
APA
Pearson, M. L., Laraway, B. J., Elias, E. R., Bilousova, G., & Haendel, M. A. (2026). More common than we thought: Hypermobile Ehlers-Danlos Syndrome, comorbidity burden, and long COVID risk in a national cohort. PLOS Digital Health, 5(11), e0001707. https://doi.org/10.1371/journal.pdig.0001707
Vancouver
Pearson ML, Laraway BJ, Elias ER, Bilousova G, Haendel MA. More common than we thought: Hypermobile Ehlers-Danlos Syndrome, comorbidity burden, and long COVID risk in a national cohort. PLOS Digital Health. 2026;5(11):e0001707. doi:10.1371/journal.pdig.0001707
BibTeX
@article{Pearson2026,
author = {Pearson, Megan L and Laraway, Bryan J and Elias, Ellen R and Bilousova, Ganna and Haendel, Melissa A},
title = {More common than we thought: Hypermobile Ehlers-Danlos Syndrome, comorbidity burden, and long COVID risk in a national cohort},
journal = {PLOS Digital Health},
year = {2026},
volume = {5},
number = {11},
pages = {e0001707},
doi = {10.1371/journal.pdig.0001707}
}
EUVIMED